Drugs / fowlpox virus vaccine vector
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00019669 | Oct 1999 → Oct 2007 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019734 | Jul 1999 → May 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fowlpox virus vaccine vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019669 ↗ |
| Known as | recombinant fowlpox vaccine | “Arm I: Patients receive recombinant fowlpox vaccine IM on day 1 followed 4 weeks later by recombinant vaccinia vaccine IM.” NCT00019734 ↗ |
| Modality | Vaccine | “fowlpox vaccine” NCT00019669 ↗ |
| Route | Intravenous | “fowlpox vaccine IV once every 4 weeks” NCT00019669 ↗ |